Answers are grounded in this paper and cite their sources.
Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control in patients with type 2 diabetes mellitus, have cardioprotective and renoprotective effects, and do not cause weight gain or significant hypoglycemia. In fact, they have been found to be effective for weight loss in patients with obesity with and without diabetes. They are now the preferred drugs to add to the regimen when oral metformin by itself is not enough to meet the patient's hemoglobin A1c goal.
No takes yet. Share an insight, caveat, or question.
Nachawi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: